Integrated Advisors Network LLC Invests $6.32 Million in Elanco Animal Health Incorporated $ELAN

Integrated Advisors Network LLC acquired a new stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN) in the first quarter, Holdings Channel.com reports. The firm acquired 264,076 shares of the company’s stock, valued at approximately $6,319,000.

Other hedge funds have also made changes to their positions in the company. NewEdge Advisors LLC grew its position in Elanco Animal Health by 133.7% during the fourth quarter. NewEdge Advisors LLC now owns 1,096 shares of the company’s stock worth $25,000 after buying an additional 627 shares in the last quarter. Root Financial Partners LLC raised its holdings in Elanco Animal Health by 50.7% in the 4th quarter. Root Financial Partners LLC now owns 1,759 shares of the company’s stock valued at $40,000 after acquiring an additional 592 shares in the last quarter. Uniplan Investment Counsel Inc. bought a new stake in shares of Elanco Animal Health in the 4th quarter worth approximately $41,000. Torren Management LLC bought a new stake in shares of Elanco Animal Health in the 4th quarter worth approximately $46,000. Finally, Farther Finance Advisors LLC grew its holdings in shares of Elanco Animal Health by 43.6% during the 4th quarter. Farther Finance Advisors LLC now owns 3,089 shares of the company’s stock worth $70,000 after purchasing an additional 938 shares in the last quarter. Institutional investors own 97.48% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the company. JPMorgan Chase & Co. boosted their price objective on Elanco Animal Health from $28.00 to $30.00 and gave the company an “overweight” rating in a research report on Thursday, May 7th. Wall Street Zen cut Elanco Animal Health from a “strong-buy” rating to a “buy” rating in a research report on Sunday, May 24th. TD Cowen lifted their price target on shares of Elanco Animal Health from $31.00 to $32.00 and gave the stock a “buy” rating in a research note on Thursday, June 18th. Citigroup boosted their price target on shares of Elanco Animal Health from $30.00 to $31.00 and gave the company a “buy” rating in a report on Thursday, May 7th. Finally, Weiss Ratings cut shares of Elanco Animal Health from a “sell (d+)” rating to a “sell (d)” rating in a research note on Monday, May 11th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Elanco Animal Health has a consensus rating of “Moderate Buy” and an average price target of $28.55.

Elanco Animal Health Price Performance

NYSE ELAN traded down $0.64 during trading on Tuesday, reaching $24.49. 707,003 shares of the company traded hands, compared to its average volume of 5,391,715. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.12 and a current ratio of 2.16. The stock’s 50 day moving average price is $23.25 and its two-hundred day moving average price is $23.71. The company has a market cap of $12.23 billion, a price-to-earnings ratio of -48.93, a P/E/G ratio of 1.63 and a beta of 1.68. Elanco Animal Health Incorporated has a 1-year low of $13.39 and a 1-year high of $27.72.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings data on Wednesday, May 6th. The company reported $0.40 earnings per share for the quarter, beating the consensus estimate of $0.34 by $0.06. Elanco Animal Health had a positive return on equity of 7.42% and a negative net margin of 4.95%.The company had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.28 billion. During the same period in the prior year, the company posted $0.37 EPS. The company’s revenue was up 14.9% compared to the same quarter last year. Elanco Animal Health has set its Q2 2026 guidance at 0.250-0.285 EPS and its FY 2026 guidance at 1.030-1.090 EPS. As a group, analysts anticipate that Elanco Animal Health Incorporated will post 1.11 EPS for the current year.

Insider Buying and Selling at Elanco Animal Health

In related news, CEO Jeffrey N. Simmons acquired 4,971 shares of the company’s stock in a transaction on Friday, May 15th. The stock was purchased at an average cost of $20.09 per share, for a total transaction of $99,867.39. Following the completion of the purchase, the chief executive officer directly owned 171,971 shares of the company’s stock, valued at $3,454,897.39. The trade was a 2.98% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Rajeev A. Modi acquired 4,911 shares of the business’s stock in a transaction on Friday, May 15th. The shares were bought at an average cost of $20.35 per share, with a total value of $99,938.85. Following the completion of the acquisition, the insider owned 160,812 shares of the company’s stock, valued at approximately $3,272,524.20. This trade represents a 3.15% increase in their position. The SEC filing for this purchase provides additional information. 1.14% of the stock is owned by insiders.

Elanco Animal Health Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.